Multitarget Drug Discovery Projects in CNS Diseases: Quantitative Systems Pharmacology as a Possible Path Forward
Citations Over TimeTop 13% of 2014 papers
Abstract
Clinical development in brain diseases has one of the lowest success rates in the pharmaceutical industry, and many promising rationally designed single-target R&D projects fail in expensive Phase III trials. By contrast, successful older CNS drugs do have a rich pharmacology. This article will provide arguments suggesting that highly selective single-target drugs are not sufficiently powerful to restore complex neuronal circuit homeostasis. A rationally designed multitarget project can be derisked by dialing in an additional symptomatic treatment effect on top of a disease modification target. Alternatively, we expand upon a hypothetical workflow example using a humanized computer-based quantitative systems pharmacology platform. The hope is that incorporating rationally multipharmacology drug discovery could potentially lead to more impactful polypharmacy drugs.
Related Papers
- → Keynote review: Structural biology and drug discovery(2005)336 cited
- → The use of constitutively active GPCRs in drug discovery and functional genomics(2002)109 cited
- → Functional cell-based uHTS in chemical genomic drug discovery(2002)56 cited
- → Using model-system genetics for drug-based target discovery(2001)32 cited
- → The Modular Approach to Ligand Discovery(2004)